Our Story
CureMeta is a Boston-based, private company founded in 2012 with the goal to discover novel targets and develop novel antibody therapeutic drugs to treat aggressive and metastatic cancers and provide real and meaningful benefits to patients suffering from these diseases.
We have filed patents on 11 antibodies that are specific to human cancers and not found in normal tissues. In 2019, we received a US patent on our lead therapeutic antibody, Bstrongximab, a therapeutic monoclonal antibody specific to the cancer target TRA-1-60, an embryonic target present in many cancers including gastric, prostate, and pancreatic cancer cells.
Patent
We have developed a proprietary antibody-discovery platform to generate monoclonal antibodies to novel and untested cancer targets. We used Bstrongximab to generate a powerful antibody-drug-conjugate, CM-09, which targets and kills gastric and pancreatic metastatic cancer.
Antibody
Our next step is to complete a human clinical phase 1 trial to generate safety and efficacy data in patients with these metastatic cancers. We anticipate minimal toxicity in the trial because the cancer target TRA-1-60 is not found in normal healthy tissues. Currently, there are no effective cancer treatments that offer any meaningful benefits or quality of life to patients suffering from these metastatic cancers. CM-09 has the potential to be a first-in-class cancer treatment to change the outlook for patients with metastatic cancers.